Lowering the C‐Reactive Protein ( CRP ) Threshold Improves Risk Stratification in Acute Ulcerative Colitis: A Propensity‐Matched Analysis

Alimentary Pharmacology and Therapeutics · Published 2026-07-18 · DOI 10.1111/apt.70825

Free full text

Authors (9)

Amirah Etchegaray, Naeman Goetz, Katherine Hanigan, Jennifer Phillips, Rina Kumar, George Tambakis, Graham Radford‐Smith, Gareth Walker, Anthony Croft

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Etchegaray, A., Goetz, N., Hanigan, K., et al. (2026). Lowering the C‐Reactive Protein ( CRP ) Threshold Improves Risk Stratification in Acute Ulcerative Colitis: A Propensity‐Matched Analysis. Alimentary Pharmacology and Therapeutics. https://doi.org/10.1111/apt.70825

Related articles

• Managing Acute Severe Ulcerative Colitis in 2025 and Beyond · Current Gastroenterology Reports · 2026 · Cites or is cited by this article
• Review Article: Biomarkers in Liver Transplantation for Hepatocellular Carcinoma: Towards Precision Medicine · Alimentary Pharmacology and Therapeutics · 2026 · Same journal
• Letter: External Validation of Hepcidin Thresholds for Predicting Response to Iron Therapy in Active Inflammatory Bowel Disease · Alimentary Pharmacology and Therapeutics · 2026 · Same journal
• Development and Validation of a Machine Learning Model to Prognosticate Hepatocellular Carcinoma · Alimentary Pharmacology and Therapeutics · 2026 · Same journal
• Natural History of Recurrent Acute Pancreatitis: Implications for Interventional Trial Design · Alimentary Pharmacology and Therapeutics · 2026 · Same journal
• Letter: Low FODMAP Therapy in Paediatric Irritable Bowel Syndrome: Balancing Efficacy, Expectancy and Safety · Alimentary Pharmacology and Therapeutics · 2026 · Same journal
• Letter: Does the Association Between Mild Endoscopic Activity and Adverse Outcomes Justify Treatment Escalation in Older Adults With Inflammatory Bowel Disease? · Alimentary Pharmacology and Therapeutics · 2026 · Same journal
• Eosinophilic Oesophagitis Beyond the Oesophagus: High Prevalence of Chronic Rhinosinusitis‐Type Symptoms and Their Impact on Symptom Severity in Swiss EoE Cohort Study Patients · Alimentary Pharmacology and Therapeutics · 2026 · Same journal
• Non‐Selective Beta‐Blocker Use Is Associated With Lower Mortality After Decompensation in Cirrhosis: A Nationwide Target Trial Emulation · Alimentary Pharmacology and Therapeutics · 2026 · Same journal
• Clinical Trial: Phase 3 Trial of Resmetirom Versus Placebo in Metabolic Dysfunction‐Associated Steatohepatitis—Reanalysis of Fibrosis Stage 2–3 Subset · Alimentary Pharmacology and Therapeutics · 2026 · Same journal